abstract |
The present invention relates to a method for the early diagnosis of a disease having a pre-inflammatory phase, or for the diagnosis of a predisposition to said disease, in a mammal, prior to any clinical signs, comprising measuring the level of at least a marker protein chosen amongst the following murine proteins Pap, Reg3a, Reg2, Cel, Reg1, Tff2, Clps, Spp1, Klk9, Klk6, Rib1, Klk5, Muc1, Cckar, Ggh, Ang, Nucb2, Pnliprp2, Pla2g1b, Ela1, Ela2, 2210010C04Rik, Pnliprp1, Itmap1, Vtn, C1qb, Sycn, Amy1, Ctrb1, 1110002023Rik, 1810014L12Rik and their respective mammalian orthologs, in a body fluid or tissue sample obtained from said mammal, comparing the measured level to a reference level for said marker protein and diagnosing the later onset of said disease if the measured level is significantly superior to the reference level. The invention also encompasses related methods and uses of these early markers of diseases having a pre-inflammatory phase. A preferred mammal is human and a preferred diseases are auto-immune diseases, especially type 1 diabetes. |